Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

February 21, 2020

Neil H. Segal, MD, PhD, discusses the current role of immunotherapy in colorectal cancer and the work being done to define its role in earlier-line settings and among patients with microsatellite stable disease.

February 20, 2020

James J. Harding, MD, discusses the evolving treatment landscape in frontline hepatocellular carcinoma and ongoing trials that may revolutionize the space.

February 19, 2020

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor sidedness on frontline treatment decisions in metastatic colorectal cancer (mCRC).

February 18, 2020

Ghassan K. Abou-Alfa, MD, discusses the treatment options that have emerged in advanced hepatocellular carcinoma and the work being done to determine optimal sequencing strategies.

February 18, 2020

David H. Ilson, MD, PhD, discusses TKI combinations under investigation in gastric cancer.

February 17, 2020

David H. Ilson, MD, PhD, discusses the treatment landscape of advanced gastric cancer and the research being done to define a role for novel agents in this space.

February 17, 2020

Andrea Cercek, MD, shares insight on treatment selection, the importance of molecular testing, and unanswered questions with tumor sidedness in patients with newly diagnosed metastatic colorectal cancer.

February 15, 2020

Jasmeet C. Singh, MD, discusses the findings of a retrospective analysis and how they may impact treatment for patients with HER2-positive breast cancer.

February 15, 2020

Eileen O'Reilly, MD, discusses the utility of PARP inhibitors in pancreatic cancer.

February 14, 2020

Yelena Janjigian, MD, highlights key updates from the 2020 Gastrointestinal Cancers Symposium and explained the impact that new data will have on clinical practice.

February 11, 2020

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the progress that has been made in the treatment of patients with hepatocellular carcinoma (HCC).

February 11, 2020

Andrea Cercek, MD, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

February 08, 2020

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.

February 07, 2020

James J. Harding, MD, discusses the goal of the phase III IMbrave150 trial in hepatocellular carcinoma (HCC).

February 07, 2020

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.

February 07, 2020

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in advanced gastric cancer.

January 31, 2020

Alexander Drilon, MD, discusses the utility of brigatinib in ALK-positive non–small cell lung cancer.

January 24, 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

January 24, 2020

Alexander Drilon, MD, discusses the potential utility of immunotherapy in ALK fusion-positive non–small cell lung cancer.

January 23, 2020

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.